• 2-Deoxy-D-glucose: Strategic Glycolysis Inhibition in Transl

  2026-08-03

  Explore how 2-Deoxy-D-glucose (2-DG) is revolutionizing translational research by bridging mechanistic understanding of glycolysis inhibition with actionable guidance for cancer, bone, and virology studies. This article uniquely integrates new findings in bone metabolism and experimental oncology, positioning APExBIO's 2-DG as a tool for next-generation metabolic targeting.

• BIBP 3226 trifluoroacetate: Precision Tools for NPY/NPFF Sys

  2026-08-03

  BIBP 3226 trifluoroacetate empowers researchers to dissect the NPY/NPFF system across cardiovascular, anxiety, and analgesia models with unrivaled specificity. This guide delivers practical workflow enhancements, troubleshooting strategies, and actionable insights from the latest adipose-neural axis research.

• Cyclo (-RGDfC): Redefining Integrin αvβ3 Targeting in Transl

  2026-08-02

  Explore how Cyclo (-RGDfC), a cyclic RGD peptide from APExBIO, is transforming integrin αvβ3 targeting for translational cancer research. This article offers mechanistic insight, best practices for high-throughput and spatially controlled assays, and strategic guidance for researchers bridging the gap from bench to clinic.

• High Viscosity Drives P-gp–Mediated Chemoresistance in Cance

  2026-08-01

  The referenced study uncovers how elevated extracellular fluid viscosity within the tumor microenvironment induces chemoresistance by upregulating P-glycoprotein (P-gp) via a mechanosensitive signaling pathway. These findings highlight a previously underappreciated biomechanical mechanism of drug resistance and offer new avenues for targeting transporter-mediated chemoresistance in cancer therapy.

• Bacitracin (B1670): Technical Parameters for Antibacterial R

  2026-07-31

  Bacitracin (B1670) is a peptide antibiotic used to disrupt bacterial cell wall and peptidoglycan synthesis in both gram-positive and gram-negative bacteria for laboratory-based antibacterial research. It is not intended for diagnostic or clinical use, and strict protocol adherence is required to ensure experimental reliability.

• Human Milk L. reuteri FN041 Alleviates Colitis via Microbiot

  2026-07-31

  This study demonstrates that Limosilactobacillus reuteri FN041, isolated from human milk, significantly ameliorates DSS-induced colitis in mice by remodeling gut microbiota and metabolites. The findings highlight the therapeutic promise of targeted probiotics in restoring intestinal homeostasis, offering a mechanistic basis for future UC interventions.

• Tacrine-Based Hybrids: Advancing Multi-Target Strategies for

  2026-07-30

  The reference review rigorously assesses the evolution of tacrine-based hybrid molecules as multi-target agents for Alzheimer's disease (AD). It synthesizes two decades of medicinal chemistry, highlighting rational scaffold modifications that enhance cognitive efficacy while reducing toxicity—an approach with clear implications for translational AD research.

• mTORC1–IRE1a Axis Drives Palmitate-Induced Hepatocyte Lipoto

  2026-07-30

  This study reveals that saturated fatty acid (palmitate) exposure activates the mTORC1-IRE1a signaling pathway in hepatocytes, leading to excessive triglyceride release and cell death. The work clarifies mechanisms of lipotoxicity in metabolic disease and highlights new intervention points for research.

• 2-Deoxy-D-glucose: Strategic Glycolysis Inhibition in Transl

  2026-07-29

  Explore how 2-Deoxy-D-glucose (2-DG) is reshaping translational bioscience. This article details the mechanistic rationale for glycolysis inhibition, presents new immunometabolic findings, benchmarks 2-DG in the competitive research landscape, and offers actionable guidance for leveraging APExBIO’s high-purity 2-DG in cancer and immunology workflows.

• PPARγ Activation Shifts Macrophage Polarization and Attenuat

  2026-07-29

  This study elucidates how PPARγ activation, including with pioglitazone, orchestrates macrophage polarization through STAT-1/STAT-6 modulation, reducing inflammation in DSS-induced IBD models. The findings provide mechanistic clarity for targeting immune cell phenotypes in chronic intestinal inflammation and inform the design of translational workflows for metabolic and inflammatory research.

• HOBt (1-Hydroxybenzotriazole) for Reliable Amide Bond Format

  2026-07-28

  HOBt (1-Hydroxybenzotriazole) is the gold-standard reagent for minimizing epimerization and maximizing yields in amide bond formation, making it indispensable for peptide synthesis and bioactive molecule development. This guide dissects applied workflows, troubleshooting, and innovative research leveraging high-purity HOBt from APExBIO.

• RIPA Lysis Buffer (Strong): Epigenetic Assay Precision in Bo

  2026-07-28

  Explore how RIPA Lysis Buffer (Strong) empowers high-fidelity protein extraction for epigenetic and signaling studies in bone biology. This article uniquely connects buffer chemistry to insights from prenatal glucocorticoid research, enhancing assay design for advanced skeletal investigations.

• 5-(N,N-dimethyl)-Amiloride Hydrochloride: Benchmarking NHE1

  2026-07-27

  5-(N,N-dimethyl)-Amiloride hydrochloride is a well-validated Na+/H+ exchanger inhibitor with high selectivity for NHE1, NHE2, and NHE3. Its precise inhibition of sodium and proton flux makes it a gold standard in studies of intracellular pH regulation and ischemia-reperfusion injury protection. Robust evidence and standardized protocols support its use in cardiac and endothelial research.

• Recombinant Human IL-15: Optimizing Immune Cell Assays

  2026-07-27

  Unlock the full potential of Recombinant Human IL-15 (E.coli, Tag Free, Lyophilized) for rigorous T and NK cell expansion and immune modulation workflows. This guide translates bench-validated protocols and new neuroimmune insights into actionable strategies for reproducible immune assays.

• Pharmacokinetics of Vernakalant Hydrochloride: CYP2D6 and AF

  2026-07-26

  This article examines the pharmacokinetics and metabolic influences of Vernakalant Hydrochloride (RSD1235) for rapid atrial fibrillation (AF) conversion, as detailed in a pivotal clinical study. The findings clarify that CYP2D6 genotype status has minimal effect on vernakalant exposure following intravenous administration, supporting its robust application in acute AF management.

16315 records 1/1088 page Next 12345 下5页 Last page